加载中
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
前收盘价
US$36.65
−US$1.15 · -3.04%
盘前
US$36.05
−US$0.60 · -1.64%
10月8日 9:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
日内区间
当前US$36.65
52周区间
当前US$36.65
盘中时间采用ET。市场数据可能有所延迟。
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
日内区间
当前US$36.65
52周区间
当前US$36.65
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 37.23亿 USD | 215.26亿 USD | 164.74亿 USD | 145.05亿 USD | 84.17亿 USD |
| 销货成本 | 3.09亿 USD | 9.85亿 USD | 2.26亿 USD | — | — |
| 毛利 | 34.14亿 USD | 205.41亿 USD | 162.48亿 USD | 145.05亿 USD | 84.17亿 USD |
| 研究与开发 | 15.6亿 USD | 97.48亿 USD | 76.3亿 USD | 55.62亿 USD | 41.81亿 USD |
| 销售、一般及管理费用 | 6.02亿 USD | 37.9亿 USD | 32.97亿 USD | 26.76亿 USD | 12.83亿 USD |
| 营业费用 | 21.63亿 USD | 138.38亿 USD | 109.27亿 USD | 82.38亿 USD | 54.64亿 USD |
| 利息收入 | 1.38亿 USD | 9.95亿 USD | 9.39亿 USD | 3.24亿 USD | 1.97亿 USD |
| 利息支出 | 6104.81万 USD | 1.2亿 USD | 2700万 USD | 2100万 USD | 1300万 USD |
| 折旧和摊销 | 7105.6万 USD | 4.13亿 USD | 2.94亿 USD | 3.62亿 USD | 2.49亿 USD |
| 营业利润 | 12.51亿 USD | 67.03亿 USD | 53.21亿 USD | 62.67亿 USD | 29.53亿 USD |
| 净利润 | 9.64亿 USD | 78.44亿 USD | 43.52亿 USD | 54.52亿 USD | 29.57亿 USD |
公司数据更新于 2026年10月8日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2018年5月1日 | 5:1 | — | — |
已生效 2018年5月1日
5:1
报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB1.58亿1.52%104.01亿 USD0.44%US$203.34+0.12%
First Trust NYSE Arca Biotechnology Index FundFBT1.18亿4.08%28.89亿 USD0.55%US$263.49-0.56%
Avantis International Equity ETFAVDE1893.78万0.10%192.77亿 USD0.23%US$89.48-1.21%
Tema Oncology ETFCANC746.72万3.67%2.03亿 USD0.99%US$40.62+0.40%
Touchstone Dynamic International ETFTDI466.45万0.89%4.53亿 USD1.04%US$46.7204-1.11%
First Trust Nasdaq BuyWrite Income ETFFTQI262.05万0.26%10.07亿 USD0.75%US$22.30-0.22%
Harding Loevner International Developed Markets Select Equity ETFLOEV223.32万2.43%9146.83万 USD0.70%US$15.85-1.02%
John Hancock Investments - Multifactor Developed International ETFJHMD195.12万0.20%9.8亿 USD0.39%US$44.05-1.14%iShares Biotechnology ETFIBBFirst Trust NYSE Arca Biotechnology Index FundFBTAvantis International Equity ETFAVDETema Oncology ETFCANCTouchstone Dynamic International ETFTDIFirst Trust Nasdaq BuyWrite Income ETFFTQIHarding Loevner International Developed Markets Select Equity ETFLOEVJohn Hancock Investments - Multifactor Developed International ETFJHMDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
